The characterization of poorly differentiated neoplasms in fine-needle aspiration (FNA) and small biopsy specimens usually requires immunohistochemistry (IHC) with a panel of markers. Because of an increasing need to preserve limited diagnostic material for tumor genotyping and a mounting demand for cost containment, the authors investigated the usefulness of dual-color IHC with antibodies directed against broad-spectrum keratins and SOX10, a neuroectodermal transcription factor consistently expressed in melanoma, in the workup of epithelioid malignant neoplasms. METHODS: A total of 107 cases of FNA cell blocks (49 cases) and small biopsies (58 cases) were selected, including 34 melanomas, 31 epithelioid/pleomorphic sarcomas, and 42 carcinomas. IHC was performed on all specimens using a peroxidase-based brown chromogen for SOX10 and an alkaline phosphatase-based red chromogen for keratins AE1/AE3. The presence or absence of staining in lesional cells was scored. RESULTS: The majority of tumors demonstrated 1 of 3 distinct patterns: 1) malignant melanomas with nuclear SOX10 (sensitivity of 94% and specificity of 95%); 2) epithelioid/pleomorphic sarcomas negative for both SOX10 and AE1/AE3 (sensitivity of 84% and specificity of 88%); and 3) carcinomas with cytoplasmic AE1/AE3 (sensitivity of 76% and specificity of 98%). In addition, a fourth pattern with cytoplasmic AE1/AE3 and nuclear SOX10 was observed in a subset of carcinomas, most notably triple-negative breast cancers. CONCLUSIONS: SOX10/keratin dual-color IHC appears to be an effective, sensitive, and specific test to distinguish between melanoma, sarcoma, and carcinoma. This approach can identify melanoma, prioritize additional studies, and limit the number of markers needed to workup an epithelioid malignant neoplasm, thereby potentially reducing costs and preserving valuable tissue for ancillary studies with which to guide therapy. Cancer Cytopathol 2018;126:179-89. V C 2018 American Cancer Society.
INTRODUCTION
The timely and accurate diagnosis of poorly differentiated epithelioid neoplasms often is challenging due to a broad differential diagnosis that includes melanoma, carcinoma, and certain sarcomas with an epithelioid morphology. Thus, a panel of immunohistochemical stains covering several lineages of differentiation often is required for the precise classification of these tumors. [1] [2] [3] This is especially true in the 3% to 5% of patients who present with cancer of an unknown primary site, 4 or the growing population of patients with a history of multiple primary malignancies. 5 As an increasing number of predictive tests for specific drugs 6 and molecular assays 7, 8 have entered into routine clinical practice, the preservation of limited biopsy material is of paramount importance to identify potential targeted therapies, 9,10 establish eligibility for immune checkpoint inhibitor therapy, 11 or to allow a patient to enroll in a clinical trial. [12] [13] [14] Moreover, as reimbursement structures change, 15 rapid and accurate diagnoses that preserve limited material by minimizing the number of immunohistochemical stains -while reducing the number of biopsies specifically designated for obtaining tissue for ancillary studies -will become more important. Dual-color immunohistochemistry (IHC) has been established as an adjunct test for the evaluation of invasive carcinoma in both the breast 16, 17 and prostate, 18, 19 and has had ever-more increasing use in the evaluation of cytology specimens including the subtyping of non-small cell lung cancer, [20] [21] [22] triaging abnormal cervical scrapings, [23] [24] [25] the detection of high-grade urothelial carcinoma, 26 identifying malignant cells in biliary brushings, 27 and the evaluation of malignant effusions. 28 The simultaneous detection of one nuclear marker and one cytoplasmic marker with dualcolor staining dramatically enhances the visibility of small foci of invasive tumor cells, 18, 19 a few tumor cells in a reactive background, 26 and/or distinct expression patterns in different settings. 28 SRY-box 10 (SOX10) encodes a member of the SOX family of transcription factors that are named for their conserved Sry-related high mobility group box domain.
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SOX10 is known to play a role in neural crest differentiation, and IHC studies have shown SOX10 to be a marker of neuroectodermal lineage that is expressed in Schwann cells, a subset of myoepithelial cells, and melanocytes. 30 A recent analysis of >5000 tumors demonstrated that SOX10 was reliably expressed in benign tumors of Schwann cell lineage and malignant melanomas, and was variably expressed in malignant peripheral nerve sheath tumors (MPSNTs), basal-type breast cancers, and a subset of salivary gland neoplasms. 31 As a marker of malignant melanoma, studies have suggested that SOX10 is more sensitive than S100 protein for the identification of metastatic melanoma, 30, 32 and its use in identifying melanocytic neoplasms in fine-needle aspiration (FNA) specimens has also been confirmed previously. 33 We hypothesized that when used in combination with a broad-spectrum keratin (AE1/AE3), a SOX10-keratin dual-color stain may be an effective first-line test in the evaluation of poorly differentiated epithelioid malignant neoplasms of unknown origin.
MATERIALS AND METHODS
The pathology archives at the Brigham and Women's Hospital were searched for FNA cell block and small/ core needle biopsy specimens with malignant diagnoses and IHC stains for S100 protein and the broadspectrum keratin AE1/AE3 ordered in the initial workup between 2010 and 2014. Cases were limited to those with a diagnosis of melanoma, epithelioid/pleomorphic sarcoma, or carcinoma. Cases with inadequate lesional material or a predominant spindle cell morphology were excluded. A cohort of 106 cases (Table 1) was identified, including 58 small/core needle biopsies and 48 FNA cell blocks with metastatic melanoma (34 cases), carcinoma (42 cases), and epithelioid/pleomorphic sarcoma (31 cases), including: epithelioid angiosarcoma (2 cases), epithelioid MPNST (2 cases), clear cell sarcoma (2 cases), proximal-type epithelioid sarcoma (2 cases), epithelioid gastrointestinal stromal tumor (GIST) (5 cases), pleomorphic liposarcoma (1 case), dedifferentiated liposarcoma (1 case), Ewing sarcoma (2 cases), and unclassified pleomorphic or epithelioid sarcoma (13 cases). One FNA case was positive for both metastatic melanoma and a high-grade serous carcinoma, and was counted as both a case of melanoma and carcinoma for the purposes of data analysis, for a total of 107 cases. When FNA cell blocks and concurrent core needle biopsies were available from the same patient, FNA cell blocks were preferentially selected for staining. A single patient sample with an FNA cell block and a concurrent core needle biopsy was stained in parallel with similar results; these Abbreviation: 1 , positive; -, negative. a A single case with both melanoma and carcinoma within the same fine-needle aspiration cell block was considered 2 cases for the purposes of data analysis. Immunoreactivity for nuclear expression of SOX10 (brown chromogen) and cytoplasmic staining for AE1/ AE3 (red chromogen) was scored and considered positive if 5% of lesional cells demonstrated moderate to strong staining for either SOX10 or AE1/AE3.
Sensitivity and specificity calculations were performed based on staining patterns. SOX10 positivity alone was considered a true-positive result for malignant melanoma, AE1/AE3 positivity alone was considered a truepositive result for carcinoma, and negative staining for both SOX10 and AE1/AE3 was considered a true-positive result for sarcoma.
RESULTS
The results of immunohistochemical staining are summarized in Table 2 .
All metastatic melanomas were negative for the broad-spectrum keratin AE1/AE3 (0 of 34 cases) and consistently demonstrated strong and diffuse nuclear staining for SOX10 in the majority of cases (32 of 34 cases; 94%) ( Fig. 1 ). There was no appreciable difference in the quality or pattern of staining between biopsy and FNA specimens.
The majority of epithelioid and pleomorphic sarcomas were found to be negative for both SOX10 and AE1/ AE3 (26 of 31 cases; 84%), including all cases of epithelioid angiosarcoma, epithelioid GIST, and unclassified pleomorphic or epithelioid sarcoma ( Figs. 2A-2B ). One epithelioid GIST demonstrated weak nuclear SOX10 expression alone that was believed to be nonspecific. However, several subtype-specific staining patterns were observed, including a group of sarcomas that were reactive for nuclear SOX10 that consisted of cases of clear cell sarcoma (2 of 2 cases; Figs. 2C-2D) and epithelioid MPNST (2 of 2 cases). In addition, 1 of 2 cases of proximal-type epithelioid sarcoma demonstrated multifocal cytoplasmic reactivity with AE1/AE3 alone (data not shown).
The most common staining pattern in carcinomas was cytoplasmic reactivity with AE1/AE3 alone (32 of 42 cases; 76%), with varying staining intensity observed among different carcinomas (Figs. 3A-3B ). The second most frequent staining pattern in the cases of carcinoma was double-negative staining for both SOX10 and AE1/ AE3 (7 of 42 cases; 17%) (Figs. 3C-3D ), which often demonstrated focal staining with another keratin (Fig. 3D  Inset) . One additional group of tumors that emerged from the current analysis was a small group of carcinomas that demonstrated reactivity for both nuclear SOX10 and cytoplasmic AE1/AE3 (3 of 42 cases; 7%). One of these tumors later was determined to be a metastasis from a triple-negative (ER/PR/HER2-negative) invasive ductal carcinoma of the breast (Figs. 4A-4B ).
Little data exist examining the diagnostic value of SOX10 in metastatic triple-negative breast cancers. To the best of our knowledge, a single recent study has examined SOX10 expression in 26 cases of metastatic breast carcinoma using a tissue microarray generated from surgical samples, 34 but no study to date has examined the expression of SOX10 in FNA cell blocks from triple-negative metastatic breast carcinomas. Given the limited data in the literature, and the potential usefulness of SOX10 IHC for detecting triple-negative breast cancer metastases, we assessed the efficacy of SOX10-keratin dual-color IHC for the identification of triple-negative breast cancer using an expanded cohort of triple-negative invasive ductal carcinomas, including 10 consecutive core needle biopsies of the breast and 5 additional FNA cell blocks of metastatic breast carcinoma. In total, 7 of 16 cases (44%) (including 2 of 6 FNA cell blocks and 5 of 10 core needle biopsies) of triplenegative breast carcinoma stained with nuclear SOX10 and cytoplasmic AE1/AE3 (Fig. 4) .
Although an uncommon situation, we observed 2 distinct tumor cell populations in a liver FNA: 1 population that was SOX10 positive and AE1/AE3 negative and another that was AE1/AE3 positive and SOX10 negative. This patient had a known history of both malignant melanoma and a high-grade serous carcinoma. The FNA specimen demonstrated a population of large, predominantly cohesive epithelioid cells with hyperchromatic irregular nuclei and coarse chromatin forming solid groups (Fig.  5A) , and a second population of dispersed and loosely cohesive epithelioid cells with eccentric nuclei with 
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March 2018 occasional large macronucleoli (Fig. 5B) . SOX10-keratin dual-color IHC performed on the cell block (Fig. 5C ) demonstrated that the less cohesive population of epithelioid cells was reactive to SOX10 alone, and a second population of epithelioid cells forming cohesive glandular structures showed reactivity for AE1/AE3 only (Fig. 5D) . The SOX10-positive melanoma cells also expressed MART-1 and HMB-45 (Fig. 5D Inset) , and the keratinpositive population expressed paired box gene 8 (PAX-8) (Fig. 5D Inset) , thereby confirming involvement by both metastatic melanoma and high-grade serous carcinoma.
DISCUSSION
In the setting of a poorly differentiated epithelioid malignant neoplasm on FNA or small biopsy in a patient with a history of multiple primary tumors, or one with widely metastatic disease without a known primary tumor, reserving tissue while reaching a definitive classification is more important and challenging than ever. The results of the current study demonstrate the usefulness of SOX10-keratin dual-color IHC for the workup of epithelioid malignant neoplasms in FNA cell blocks and small/core needle biopsies. The current study identified 4 distinct staining patterns: 1) nuclear positivity for SOX10 alone; 2) "double negative" for SOX10 and AE1/AE3; 3) AE1/AE3 positivity alone; and 4) a subset of "double-positive" carcinomas that stained for nuclear SOX10 and cytoplasmic AE1/AE3. Based on the current study data, we propose an algorithm for the workup of poorly differentiated epithelioid malignant neoplasms in FNA and small biopsy specimens (Fig. 6) .
Nuclear reactivity for SOX10 alone was both sensitive (94%) and specific (95%) for metastatic melanoma, with only 2 cases of melanoma found not to express SOX10 (Table 2) . Similar to previous studies, 35 additional samples that demonstrated strong immunoreactivity for SOX10 were 2 cases each of clear cell sarcoma and epithelioid MPNST. Given the high sensitivity and specificity of nuclear immunoreactivity for SOX10 and the lack of keratin expression for malignant melanoma, it is reasonable that SOX10 staining alone can be diagnostic for metastatic melanoma in patients with a high clinical suspicion for the disease and could rapidly suggest the diagnosis of melanoma in patients presenting with an unknown primary tumor, or a history of multiple primary tumors, leading to substantial reductions in the number of stains needed to reach a diagnosis. In the current study cohort, based on a known history of melanoma, 24 of 34 cases had a high index of suspicion for metastatic melanoma. In this group of cases, the mean number of immunostains in the original workup was 4.4. Conversely, in the group of tumors presenting as an unknown primary or in patients with a history of multiple malignancies (10 of 34 cases), the mean number of IHC stains used in the workup was 9.0. Some have estimated the cost of a single IHC stain (including both technical and professional charges) at slightly greater than $300. 36 Given the potential reduction in stains needed to diagnose a melanoma, these are not insubstantial benefits to centers with large volumes, in which cost savings could easily reach $600 to $1200 per case. In addition to the potential cost savings, in some small biopsy samples, predictive biomarker testing (such as BRAF gene sequencing and programmed death-ligand 1 (PD-L1) IHC) may not be possible if the tissue block is exhausted by numerous sections for diagnostic IHC. Moreover, the estimated global cost savings could be even higher in cases in which repeat tissue sampling solely for additional ancillary testing could be avoided. The second most frequent pattern observed in the current study was a group of tumors that were negative for both SOX10 and AE1/AE3, which was most commonly observed in epithelioid/pleomorphic sarcomas (26 of 31 cases). Among sarcomas, there were notable staining exceptions for clear cell sarcoma and epithelioid MPNST, which were reactive for nuclear SOX10, and a single case of proximal-type epithelioid sarcoma, which had multifocal positivity for AE1/AE3 alone. Thus, although the doublenegative pattern is reasonably sensitive (84%) and specific (88%) for sarcomas, there is subtype-specific variability that emphasizes the need for additional IHC or other ancillary studies to confirm the diagnosis. It is interesting to note that the double-negative pattern also was observed in a significant subset of poorly differentiated carcinomas (7 of 42 cases) (Figs. 3C-3D) , and also would be expected in various hematopoietic malignancies, such as a large cell lymphoma or a plasma cell neoplasm, that can enter the differential diagnosis of an epithelioid malignancy. These results suggest that additional IHC for other broadspectrum keratins and lymphoid markers may be needed to exclude a carcinoma or hematopoietic malignancy.
Immunoreactivity for AE1/AE3 alone was highly specific (98%) for carcinoma in our selected cohort. However, the 7 cases of carcinoma that were found to be double negative for SOX10 and AE1/AE3 demonstrated the modest sensitivity (76%) of this result. A review of the original clinical workup for the 7 double-negative carcinomas demonstrated that the majority of these cases had limited or focal keratin expression of another broad-spectrum keratin (clone MNF-116) or keratin 8 (clone CAM5.2). Thus, replacing AE1/AE3 with a keratin cocktail in the dualcolor IHC protocol would likely increase the sensitivity for detecting carcinomas. However, this approach conceivably would reduce the specificity for detecting carcinoma because several epithelioid soft tissue neoplasms, such as epithelioid sarcoma or an epithelioid vascular tumor, may have limited keratin expression. It is interesting to note that a subset of carcinomas emerged that were double positive for cytoplasmic AE1/AE3 and nuclear SOX10. In our original study cohort, we identified 3 carcinomas that shared this pattern, including 2 cases of poorly differentiated carcinoma of lung origin, both with modest nuclear SOX10 staining, which previously has been observed at low frequencies, 31 as well as a single case of triple-negative breast carcinoma that had strong SOX10 and keratin expression (Figs. 4A-4B ). Previous work has reported that approximately two-thirds of triple-negative breast carcinomas, including basal-type and metaplastic carcinomas, express SOX10. 37 The expanded cohort of triple-negative breast carcinomas in the current study demonstrated dual SOX10-AE1/AE3 positivity in approximately one-half of the tumors examined (7 of 16 cases). This is similar to the results of a recently published study by Nelson et al, who noted frequent SOX10 expression (71%) in patients with ER negative metastatic breast carcinoma. 34 In addition,
Miettinen et al have shown consistent SOX10 expression in multiple malignant salivary gland neoplasms, including acinic cell carcinoma, adenoid cystic carcinoma, epithelialmyoepithelial carcinoma, and myoepithelial carcinoma. 31 Thus, although the number of carcinomas that are double positive is fairly limited, we believe the presence of dual SOX10-keratin positivity is highly suggestive of a breast, salivary gland, or myoepithelial soft tissue neoplasm and may direct subsequent studies to rapidly identify an uncommon carcinoma arising at an occult primary site in the setting of a metastatic poorly differentiated carcinoma without a known primary tumor. Finally, in the evaluation of patients with a history of multiple malignant primary tumors, the use of a single dual-color IHC stain has the potential to identify different, but morphologically similar, epithelioid malignant neoplasms in one sample (Fig. 5) , thereby streamlining the workup by identifying a malignant melanoma component quickly and focusing subsequent IHC toward the identification of a specific line of differentiation or site of origin of the other tumor component.
One potential pitfall of using SOX10-keratin dualcolor IHC in the evaluation of FNA specimens is the presence of significant contaminating benign epithelial cells that may give the false impression of a keratin-positive carcinoma. There are several scenarios in which this could occur, including endobronchial ultrasound-guided FNAs in which reactive bronchial cells may be mistaken for a lesion or an endoscopic ultrasound-guided FNA of a lesion associated with the upper gastrointestinal tract or pancreas that may collect significant numbers of gastrointestinal epithelial cells, both of which are situations that could potentially give the false impression of a keratin-positive carcinoma.
The use of multiplexed IHC stains in cytology specimens has grown dramatically in the past 5 to 7 years (Table  3) . [20] [21] [22] [23] [24] [25] [26] [27] [28] Studies have shown the usefulness of these stains in triaging patients with abnormal cervical cytology, [23] [24] [25] evaluating malignant effusions, 28 identifying high-grade urothelial carcinomas, 26 detecting malignancy in biliary brushings, 27 and the subtyping of non-small cell lung carcinoma. [20] [21] [22] The last example especially highlights the need to preserve limited diagnostic material for ancillary studies such as fluorescence in situ hybridization (FISH) for ALK and ROS1 rearrangements, next-generation sequencing (NGS), and PD-L1 testing, all of which have become standard practice for the management of lung adenocarcinomas. Although several recent studies have highlighted the benefit of using cytology specimens for NGS, 38-43 the majority of NGS and FISH studies are still performed on formalin-fixed paraffin-embedded tissue as not all laboratories have validated routine cytologic preparations for molecular testing. Thus, preserving limited cell block material is of great importance for many laboratories to limit the number of biopsy procedures specifically intended to obtain material for molecular testing. Moreover, given the everincreasing number of ancillary tests making their way into clinical practice, we can expect continued growth in requests to apply these tests to archival material. Should an additional biopsy be needed, these procedures may require image guidance, which significantly increases costs, delays treatment and, depending on the anatomic location, could pose significant risks to the patient. Preserving small biopsy specimen material potentially can limit the number of these biopsies.
The rapid adoption of dual-color IHC throughout the field of cytology suggests that this is a trend that will continue to increase in the coming years as more applications become apparent in which the rapid/simultaneous evaluation of multiple markers addresses a clinical need that facilitates patient care.
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